AN
Adlai Nortye Ltd.
ANL · NASDAQ
$15.53 -2.91% (-$0.46)
1M +9.44%
Market Cap $824.3M
P/E Ratio -
Div. Yield -
ROE 21.82%
Bulios Fair Price
$13.3
14.4% downside
Current Price
$15.53
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ANL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
27 /100
Expensive P/B 3.84x
P/S 41.89x
PEG N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak FCF margin 296.00%
Op. margin 113.28%
Gross margin 100.00%
Quality
1 /100
Poor Asset turnover 0.08x
ROA 9.07%
ROIC 9.23%
Debt
100 /100
Low Current ratio 9.55x
Debt/Equity 0.12x
Net debt/EBITDA N/A
Stability
26 /100
Unstable EPS volatility 101.30%
Profitable years 0
Beta 1.15x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ANL
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Yang Lu
Employees
109
Headquarters
Singapore
Upcoming events
03 MAR
Earnings
Upcoming earnings report